Gene Mack is CFO and Interim CEO of Gain Therapeutics, Inc.. Currently has a direct ownership of 14,400 shares of GANX, which is worth approximately $24,768. The most recent transaction as insider was on Aug 09, 2024, when has been sold 14,400 shares (Common Stock) at a price of $1.01 per share, resulting in proceeds of $14,544. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 14.4K
0% 3M change
n/a 12M change
Total Value Held $24,768

Gene Mack Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 09 2024
BUY
Open market or private purchase
$14,544 $1.01 p/Share
14,400 Added 50.0%
14,400 Common Stock
GM

Gene Mack

CFO and Interim CEO
Bethesda, MD

Track Institutional and Insider Activities on GANX

Follow Gain Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GANX shares.

Notify only if

Insider Trading

Get notified when an Gain Therapeutics, Inc. insider buys or sells GANX shares.

Notify only if

News

Receive news related to Gain Therapeutics, Inc.

Track Activities on GANX